FDA approval fuels Boehringer’s biosimilar challenge to AbbVie’s Humira
Yesterday Boehringer Ingelheim won the FDA’s approval for a high-concentration and citrate-free version of its Humira biosimilar Cyltezo, targeting AbbVie’s blockbuster drug.
If you are not happy with the results below please do another search
Yesterday Boehringer Ingelheim won the FDA’s approval for a high-concentration and citrate-free version of its Humira biosimilar Cyltezo, targeting AbbVie’s blockbuster drug.
Mariana Oncology is working on novel radioligand cancer therapies (RLTs) that have not yet been tested on humans.
Apart from an impact of about $40 million cut in inventory, Regeneron said changing market dynamics that resulted in lower volumes and lower selling price also hurt eye drug Eylea sales.
Citing a strategic prioritization by Moderna, Metagenomi announced that the partners have “mutually agreed” to terminate their gene editing agreement.
Dedicated to the growth and development of Peregrine, Schmid has been elevated to partner, and Deng was promoted to senior content strategist, with the responsibility of leading projects in collaboration with an interdepartmental team of strategists, copywriters, art directors, and account service representatives to help clients identify opportunities for managed market–focused content development.
In a bid to improve competition in the industry, the U.S. Federal Trade Commission is challenging the patents of 20 different pharmaceutical products, disputing the accuracy and relevance of their patents.
Neurocrine Biosciences won the FDA’s approval for a sprinkle capsule formulation of Ingrezza, providing a more convenient route of treatment for Huntington’s disease patients with trouble swallowing.
Denmark will start putting patients suffering from type 2 diabetes on cheaper drugs before prescribing so-called GLP-1 drugs such as Novo Nordisk’s Ozempic, the Danish Medicines Agency.
Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug candidates when it reports quarterly earnings on Thursday.
Johnson & Johnson is moving forward with a $6.475 billion proposed settlement of tens of thousands of lawsuits alleging that its baby powder and other talc products contain asbestos and cause ovarian cancer, the company said today in a statement.